CORTAPRED - 10 mg, a medication belongs to the class of long-acting corticosteroid with anti-inflammatory properties. It is primarily used to treat various inflammatory conditions and autoimmune diseases.

CORTAPRED - 10 mg is highly effective in reducing redness and swelling, as well as relieving pain and irritation caused by many inflammatory conditions.

CORTAPRED - 10 mg is considered a safe therapeutic option for significant symptom improvement and enhancing the quality of life for individuals.

Each tablet of CORTAPRED - 10 mg contains 10 mg Prednisolone.

Allergic states:

CORTAPRED - 10 mg is indicated for severe, incapacitating allergic conditions that are unresponsive to conventional treatment such as bronchial asthma, serum sickness, and drug hypersensitivity reactions.

Skin conditions:

CORTAPRED - 10 mg is used for life-threatening or refractory skin conditions unresponsive to conventional treatments, such as bullous dermatitis, exfoliative dermatitis, fungal infections, and pemphigus.

Collagen disorders:

CORTAPRED - 10 mg is effective in conditions associated with collagen diseases such as systemic lupus erythematosus, polymyositis, polymyalgia rheumatica, temporal (giant cell) arteritis, mixed connective tissue disease syndrome, and acute rheumatic carditis.

Endocrine disorders:

CORTAPRED - 10 mg is effective in cases of primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, and hypercalcemia associated with cancer.

Gastro-Intestinal disease:

CORTAPRED - 10 mg is used to help patients through the critical phase of illness in cases of inflammatory bowel disease and ulcerative colitis.

Hematological disorders:

CORTAPRED - 10 mg is recommended for selected cases of various blood dyscrasias, including hemolytic anemia and thrombocytopenic purpura.

Neoplastic diseases:

CORTAPRED - 10 mg can be used to treat leukemias and lymphomas in adults, and acute leukemia in children.

Renal Disorders:

CORTAPRED - 10 mg is considered an effective option for treating nephrotic syndrome.

Respiratory disease:

CORTAPRED - 10 mg is used to treat sarcoidosis (especially with hypercalcemia), and fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy.

Rheumatic disorders:

CORTAPRED - 10 mg is indicated for short-term adjunctive therapy in cases of acute gout, rheumatoid arthritis, and psoriatic arthritis.

Children:

CORTAPRED - 10 mg may cause growth delay in infants, children, and adolescents, which may be irreversible. Therefore, treatment should be limited to the lowest effective dose and the shortest possible duration. Consult a doctor before administering CORTAPRED - 10 mg to children or adolescents, as it may affect their growth.

Pregnancy& breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking CORTAPRED - 10 mg.

Pregnancy Category: C.

CORTAPRED - 10 mg should not be used during breastfeeding because small amounts of CORTAPRED - 10 mg appear in breast milk.

Infants whose mothers take high doses of CORTAPRED - 10 mg may suffer from adrenal suppression, but theoretically, the benefits of breastfeeding outweigh any risk. Therefore, it is recommended to monitor infants for any signs of adrenal suppression.

Adults:

Allergic and Dermatological Conditions:

The initial dose of CORTAPRED - 10 mg is typically 1 tablet (10 mg) daily.

Collagen Diseases:

The initial dose of CORTAPRED - 10 mg ranges from 2 tablets (20 mg) to 3 tablets (30 mg) daily.

When symptoms are more severe, higher doses may be recommended as per the doctor's instructions.

Hematologic and Lymphatic Disorders:

The initial dose of CORTAPRED - 10 mg ranges from 1 tablet (10 mg) to 6 tablets (60 mg) daily and should be decreased after achieving an adequate clinical or hematologic response.

Rheumatoid Arthritis:

The initial dose of CORTAPRED - 10 mg is typically 1 tablet (10 mg) daily. The lowest maintenance dose is recommended daily as per the doctor's instructions.

Higher doses may be necessary to induce remission in acute leukemia.

Children and Adolescents:

Fractions of the adult dosage may be used (e.g., 75% of the adult dose for children aged 12 years of age, 50% of the adult dose for children aged 7 years of age, and 25% of the adult dose for children aged 1 year of age), but clinical factors must be taken into consideration.